Eagle Pharmaceuticals. has filed a patent for stable pemetrexed formulations using a non-aqueous solvent, remaining stable for at least 48 hours post-dilution at 2° C. to 8° C. The patent also covers formulations remaining stable for 24 months under the same conditions. GlobalData’s report on Eagle Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eagle Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eagle Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Eagle Pharmaceuticals's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Stable pemetrexed formulations for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Eagle Pharmaceuticals Inc

A recently filed patent (Publication Number: US20240009199A1) discloses a method for treating pleural mesothelioma or non-squamous, non-small cell lung cancer in patients in need of treatment. The method involves providing a liquid pharmaceutical composition containing specific concentrations of pemetrexed diacid, propylene glycol, tromethamine, and optional HCl in water. The composition is intended for administration to patients requiring treatment for these specific types of cancer.

The patent further details variations in the composition, with specific concentrations of the active ingredients tailored for treating pleural mesothelioma, non-squamous, non-small cell lung cancer, or a combination of both. Additionally, the patent specifies that the liquid pharmaceutical composition can be stored in a vial, with the option for it to be a multi-dose vial. These specific formulations and storage options aim to provide an effective and convenient treatment method for patients suffering from these types of cancer, potentially offering a more targeted and efficient approach to managing these conditions.

To know more about GlobalData’s detailed insights on Eagle Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies